Study Supports Zolinza for Patients with Indolent B-cell Lymphomas

Researchers say the drug might improve outcomes in some patients with indolent and incurable B-cell lymphomas.

Right now, Zolinza is only FDA-approved for the treatment of relapsed or recurrent cutaneous T-cell lymphoma.

Japanese researchers carried out a multi-center phase II study of Zolinza (vorinostat) in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma and mantle cell lymphoma.

They recruited 50 non-Hodgkin's lymphoma patients (39 who had follicular lymphoma) who had relapsed following treatment. Relapse is extremely common with these indolent diseases.

Study focuses on response rate, safety, tolerance

Patients received 200 mg of Zolinza twice daily for 14 consecutive days in a 21-day cycle. Scientists think Zolinza works by inhibiting a class of enzymes called histone deacetylases. Zolinza treatments continued until the non-Hodgkin's lymphoma began to progress again or until the side effects became too much to continue. The primary endpoint was overall response rate in follicular lymphoma patients and safety and tolerance in the rest of the test subjects.

The overall response rate among the relapsed follicular lymphoma patients was 49 percent. The most serious complications from Zolinza treatment were a reduction in platelets and certain white blood cells, both of which they considered to be manageable.

"Vorinostat (Zolinza) offers sustained antitumor activity in patients with relapsed or refractory follicular lymphoma with an acceptable safety profile," the team wrote.

Their findings appear in the British Journal of Haematology.

Source: Digital Journal

b cell lymphoma tretment

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...